AbdA Antibody

• Description :

  AbdA Antibody_x000D_ Catalog number: B2015316_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 50 ug_x000D_ Molecular Weight or Concentration: N/A_x000D_ Supplied as: Solid_x000D_ Applications: a molecular tool for various biochemical applications_x000D_ Storage: 2-8°C_x000D_ Keywords: AbdA Antibody_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Karch F, Bender W, Weiffenbach B. abdA expression in Drosophila embryos Genes Dev. 1990 Sep;4(9):1573-87._x000D_ 2: Herndon K, Dewitt A, Gillion A, Pattanaik D. Infusion-related angioedema associated with infliximab-abda: Case report Am J Health Syst Pharm. 2021 Jan 5;78(2):108-112._x000D_ 3: Westerkam LL, Tackett KJ, Sayed CJ. Comparing the Effectiveness and Safety Associated With Infliximab vs Infliximab-abda Therapy for Patients With Hidradenitis Suppurativa JAMA Dermatol. 2021 Jun 1;157(6):708-711._x000D_ 4: Deaner JD, Srivastava SK, Hajj-Ali RA, Lowder CY, Venkat AG, Baynes K, Sharma S. Recurrence Rates of Inflammation after Switching from the Originator Infliximab to Biosimilar Infliximab-abda for Noninfectious Uveitis Am J Ophthalmol. 2021 May;225:172-177._x000D_ 5: O'Connell DM, Nachreiner J, Shu X, Terry E, Imburgia T, Vanderloo J, Lasarev MR, Bogenschutz M. Rapid Infliximab Biosimilar Infusion in Children With Inflammatory Bowel Disease J Pediatr Gastroenterol Nutr. 2022 May 1;74(5):605-609._x000D_ 6: Kim JY, Bhat S. Safety of Rapid Infliximab Biosimilar Infusions in Patients With Inflammatory Bowel Disease Ann Pharmacother. 2022 Mar;56(3):280-284._x000D_ 7: Bhat S, Altajar S, Shankar D, Zahorian T, Robert R, Qazi T, Shah B, Farraye FA. Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb J Manag Care Spec Pharm. 2020 Apr;26(4):410-416._x000D_ 8: Hanrahan C, Lee T. Network meta-analysis of infliximab biosimilars for the treatment of rheumatoid arthritis Am J Health Syst Pharm. 2021 Mar 31;78(8):697-704._x000D_ 9: Socal MP, Ezebilo I, Bai G, Anderson GF. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab Am J Health Syst Pharm. 2021 Jan 22;78(3):216-221._x000D_ 10: Baker JF, Leonard CE, Lo Re V 3rd, Weisman MH, George MD, Kay J. Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives Arthritis Rheumatol. 2020 Jul;72(7):1067-1071. _x000D_ _x000D_ Products Related to AbdA Antibody can be found at Antibodies

• Short Description :

  Catalog Number: B2015316 (50 ug)

• Weight :

  0.15

• Length :

  2

• Width :

  0.5

• Height :

  0.5

• CAS Number :

  9007-83-4